In pharmaceutical sales, in order to drive sales despite the limited or controversial efficacy, several strategies may be utilized: 1. **Targeted marketing**: Pharmaceutical companies may position their products to specific populations or distribution channels, emphasizing their benefits or claims, appealing to groups that are more susceptible to promotional messages. 2. **Influencer-based marketing**: By working closely with influential physicians, researchers, or social media figures, companies can build credibility and recognition within the industry despite limited efficacy data. 3. **Direct-to-consumer advertising**: Direct-to-consumer (DTC) advertising can create demand for a product even if the evidence for efficacy is unsatisfactory. This type of advertising often emphasizes the potential benefits of a product while downplaying or simplifying the risks. 4. **Patient support programs**: Pharmaceutical companies may create patient support programs that appear to altruistically provide benefits such as education, encouragement, or financial assistance, but in fact drive product sales and build brand loyalty. 5. **Benefit rhetoric**: Sometimes sales representatives may exaggerate the efficacy of a product, downplay the risks, or make claims that have not yet been fully substantiated in order to convince medical professionals to adopt the drug. 6. **Selective presentation of scientific research**: Pharmaceutical companies may only publish or promote studies that support the effectiveness of their products, while ignoring or downplaying studies that found limited or uncertain benefits. 7. **Social media strategies**: Pharmaceutical companies may fund third-party organizations, research, or advocacy groups to promote the benefits of their products, while perhaps not clearly disclosing their funding sources or conflicts of interest. 8. **Developing new metrics or standards**: Companies may propose new metrics or standards to measure the effectiveness of their products that may be questioned by the industry but help to present results in an optimistic light. 9. **Exploiting emotional appeals**: Pharmaceutical companies may use emotional stories, misleading statistics, or sensational marketing strategies to create demand for their products that blatantly contradict scientific evidence. 10. **Cortiz inhibitor supplements or reducers**: Pharmaceutical companies may propose supplements or reducers to alleviate the side effects of a drug, which may increase sales of the original drug. 11. **Partnerships and influence**: Pharmaceutical companies can gain credibility and visibility by partnering with prestigious research institutions, hospitals, or professional organizations, and use this relationship to promote their products even when the evidence for efficacy is limited. 12. **Therapeutic area expansion**: Pharmaceutical companies may attempt to expand their potential customer base by adapting their products for new indications or populations, even if the evidence for the initial approval does not support such expansion. It is important to note that these strategies may not always be malicious or deceptive. It is a delicate balancing act that companies must balance between the need to market their products to provide revenue and maintain business with the need to present scientific evidence accurately and fairly. Sometimes, companies use these strategies to highlight important therapeutic benefits even if the evidence is evolving or still incomplete.